Qingmin Chen Email

VP, Head in vivo Pharmacology . Atalanta Therapeutics

Current Roles

Employees:
84
Revenue:
$13M
About
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.
Atalanta Therapeutics Address
51 Sleeper Street
Boston, MA
United States
Atalanta Therapeutics Email

Past Companies

Atalanta TherapeuticsVice President, Head of in vivo Pharmacology
Atalanta TherapeuticsSenior Director
Renascent BiosciencesSenior Director

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.